scholarly journals A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Sandeep Ramalingam ◽  
Catriona Graham ◽  
Jenny Dove ◽  
Lynn Morrice ◽  
Aziz Sheikh
Keyword(s):  
Randomised Controlled Trial ◽  
Hypertonic Saline ◽  
Common Cold ◽  
Controlled Trial ◽  
Nasal Irrigation ◽  
The Common ◽  
Randomised Controlled

scholarly journals Randomised controlled trial of rhinothermy for treatment of the common cold: a feasibility study

BMJ Open ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. e019350 ◽  
Author(s):  
Susanne van de Hei ◽  
Steven McKinstry ◽  
George Bardsley ◽  
Mark Weatherall ◽  
Richard Beasley ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Vitamin C ◽  
Feasibility Study ◽  
Common Cold ◽  
Controlled Trial ◽  
Secondary Outcome ◽  
Pcr Analysis ◽  
Control Group ◽  
The Common ◽  
Randomised Controlled

ObjectiveTo determine the feasibility of a randomised controlled trial (RCT) of rhinothermy for the common cold.DesignOpen label, randomised, controlled feasibility study.SettingSingle-centre research institute in New Zealand recruiting participants from the community.Participants30 adult participants with symptoms of a common cold, presenting within 48 hours of the onset of symptoms.InterventionsParticipants were randomly assigned 2:1 to receive either 35 L/min of 100% humidified air at 41°C via high flow nasal cannulae, 2 hours per day for up to 5 days (rhinothermy), or vitamin C 250 mg daily for 5 days (control).Primary and secondary outcome measuresThe primary outcome was the proportion of screened candidates who were randomised. Secondary outcomes included: proportion of randomised participants who completed the study; modified Jackson scores from randomisation to 10 days after initiation of randomised regimen; time until feeling ‘a lot better’ compared with study entry; time until resolution of symptoms or symptom score at 10 days postrandomisation; proportion of organisms identified by PCR analysis of nasal swabs taken at baseline; the patterns of use of the rhinothermy device; estimated adherence of the control group; and rhinothermy device tolerability.ResultsIn all 30/79 (38%, 95% CI 27% to 50%) of potential participants screened for eligibility were randomised. Rhinothermy was well tolerated, and all randomised participants completed the study (100%, 95% CI 88% to 100%). The reduction from baseline in the modified Jackson score was greater with rhinothermy compared with control at days 2, 3, 4, 5 and 6, with the maximum difference at day 4 (−6.4, 95% CI −9.4 to −3.3). The substantial clinical benefit threshold for modified Jackson score was a 5-unit change.ConclusionsThis study shows that an RCT of rhinothermy compared with low-dose vitamin C in the treatment of the common cold is feasible.Trial registration numberACTRN12616000470493; Results.

Megadose vitamin C in treatment of the common cold: a randomised controlled trial

2002 ◽  
Vol 176 (5) ◽  
pp. 298-299
Author(s):  
Carmen Audera ◽  
Roger V Patulny ◽  
Beate H Sander ◽  
Robert M Douglas
Keyword(s):  
Randomised Controlled Trial ◽  
Vitamin C ◽  
Common Cold ◽  
Controlled Trial ◽  
The Common ◽  
Randomised Controlled

scholarly journals Rhinothermy delivered by nasal high flow therapy in the treatment of the common cold: a randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. e047760
Author(s):  
Grace Bird ◽  
Irene Braithwaite ◽  
James Harper ◽  
Iris Koorevaar ◽  
Marthe van den Berg ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Common Cold ◽  
Symptom Severity ◽  
Controlled Trial ◽  
High Flow ◽  
Cold Symptom ◽  
The Common ◽  
Randomised Controlled ◽  
Humidified Air ◽  
Single Blind

BackgroundThe common cold is the most common infectious disease affecting humans and has a substantial economic impact on society. Human rhinoviruses, which cause almost two-thirds of colds, have demonstrated temperature-dependent replication which is optimal between 33°C and 35°C.MethodsThis randomised, single-blind, parallel-group trial completed at a single-centre in New Zealand, recruited 170 participants aged 18–75 years (mean age 27.5 years) who were within 48 hours of common cold symptom onset and had a symptom score (the Modified Jackson Score (MJS)) ≥7 and a negative point-of-care test for influenza. Participants were blinded to the intervention and randomised (1:1) to 5 days of either nasal high flow rhinothermy (rNHF) (100% humidified air delivered at 35 L/min and 41°C for 2 hours daily) (n=85) or ‘sham’ rhinothermy (100% humidified air delivered at 10 L/min and 31°C for 10 min daily) (n=85) and completed daily symptom diaries, which included the MJS, for 14 days, to investigate whether rNHF reduced common cold symptom severity and duration compared with ‘sham’ rhinothermy.ResultsAn intention-to-treat superiority analysis included all randomised participants and showed no difference between treatment groups for the primary outcome, the day 4 MJS analysed by analysis of covariance: mean (SD) 6.33 (3.97) for rNHF vs 5.8 (3.15) for ‘sham’; estimated difference (95% CI) 0.37 (−0.69 to 1.42), p=0.49. There was no difference in time until resolution of symptoms: mean (SD) 5.96 (4.47) days for rNHF vs 6.42 (4.09) days for ‘sham’; estimated difference (95% CI) 1.02 (0.75 to 1.38), p=0.91. There were no serious adverse events related to the study treatments.ConclusionsThis well-powered, single-blind randomised controlled trial does not provide evidence that 5 days of rNHF (100% humidified air heated to 41°C delivered at 35 L/min for 2 hours daily) reduces common cold symptom severity or duration. However, investigation of rNHF in the treatment of influenza is warranted.Trial registration numberACTRN12617001340325.

Megadose vitamin C in treatment of the common cold: a randomised controlled trial

2002 ◽  
Vol 176 (5) ◽  
pp. 298-299 ◽  
Author(s):  
Luis Vitetta ◽  
Avni Sali ◽  
Bill Paspaliaris ◽  
Nicola J Reavley
Keyword(s):  
Randomised Controlled Trial ◽  
Vitamin C ◽  
Common Cold ◽  
Controlled Trial ◽  
The Common ◽  
Randomised Controlled

Mega‐dose vitamin C in treatment of the common cold: a randomised controlled trial

2001 ◽  
Vol 175 (7) ◽  
pp. 359-362 ◽  
Author(s):  
Carmen Audera ◽  
Roger V Patulny ◽  
Beate H Sander ◽  
Robert M Douglas
Keyword(s):  
Randomised Controlled Trial ◽  
Vitamin C ◽  
Common Cold ◽  
Controlled Trial ◽  
The Common ◽  
Randomised Controlled

scholarly journals High flow therapy versus hypertonic saline in bronchiolitis: randomised controlled trial

2014 ◽  
Vol 99 (6) ◽  
pp. 511-515 ◽  
Author(s):  
M. Bueno Campana ◽  
J. Olivares Ortiz ◽  
C. Notario Munoz ◽  
M. Ruperez Lucas ◽  
A. Fernandez Rincon ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Hypertonic Saline ◽  
Controlled Trial ◽  
High Flow ◽  
Randomised Controlled

scholarly journals The effect of 3% and 6% hypertonic saline in viral bronchiolitis: a randomised controlled trial

2014 ◽  
Vol 44 (4) ◽  
pp. 913-921 ◽  
Author(s):  
Jasmijn Teunissen ◽  
Anne H.J. Hochs ◽  
Anja Vaessen-Verberne ◽  
Annemie L.M. Boehmer ◽  
Carien C.J.M. Smeets ◽  
...  
Keyword(s):  
Sodium Chloride ◽  
Randomised Controlled Trial ◽  
Hospital Stay ◽  
Hypertonic Saline ◽  
Normal Saline ◽  
Controlled Trial ◽  
Tube Feeding ◽  
Length Of Hospital Stay ◽  
Supplemental Oxygen ◽  
Randomised Controlled

Bronchiolitis is a common disorder in young children that often results in hospitalisation. Except for a possible effect of nebulised hypertonic saline (sodium chloride), no evidence-based therapy is available. This study investigated the efficacy of nebulised 3% and 6% hypertonic saline compared with 0.9% hypertonic saline in children hospitalised with viral bronchiolitis.In this multicentre, double-blind, randomised, controlled trial, children hospitalised with acute viral bronchiolitis were randomised to receive either nebulised 3%, 6% hypertonic saline or 0.9% normal saline during their entire hospital stay. Salbutamol was added to counteract possible bronchial constriction. The primary endpoint was the length of hospital stay. Secondary outcomes were need for supplemental oxygen and tube feeding.From the 292 children included in the study (median age 3.4 months), 247 completed the study. The median length of hospital stay did not differ between the groups: 69 h (interquartile range 57), 70 h (IQR 69) and 53 h (IQR 52), for 3% (n=84) and 6% (n=83) hypertonic saline and 0.9% (n=80) normal saline, respectively, (p=0.29). The need for supplemental oxygen or tube feeding did not differ significantly. Adverse effects were similar in the three groups.Nebulisation with hypertonic saline (3% or 6% sodium chloride) although safe, did not reduce the length of stay in hospital, duration of supplemental oxygen or tube feeding in children hospitalised with moderate-to-severe viral bronchiolitis.

Sign in / Sign up

Export Citation Format

Share Document